BusinessAbeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis BullosaBy Nasdaq OMXMay 25, 2017, 12:10 PM UTC
BusinessAbeona Therapeutics to Present at Multiple Upcoming ConferencesBy Nasdaq OMXMay 19, 2017, 12:06 PM UTC
BusinessAbeona Therapeutics to Present at Multiple Upcoming ConferencesBy Nasdaq OMXMay 19, 2017, 12:06 PM UTC
BusinessAbeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa from the Society for Investigative Dermatology ConferenceBy Nasdaq OMXMay 2, 2017, 12:05 PM UTC
BusinessAbeona Therapeutics Announces EB-101 Clinical Update to be Presented at the Society for Investigative Dermatology Annual MeetingBy Nasdaq OMXApr 25, 2017, 12:05 PM UTC
BusinessAbeona Therapeutics Reports Q4 2016 Financial Results and Business HighlightsBy Nasdaq OMXMar 31, 2017, 12:05 PM UTC
BusinessAbeona Therapeutics to Present at Multiple Upcoming Investor ConferencesBy Nasdaq OMXMar 13, 2017, 12:15 PM UTC
BusinessAbeona Therapeutics Receives Orphan Drug Designation in the European Union for EB-101 Gene Therapy Clinical Trial for Epidermolysis BullosaBy Nasdaq OMXMar 8, 2017, 1:15 PM UTC
